Loading
A phase 1/2 trial of Rocbrutinib in mantle cell lymphoma and diffuse large b-cell lymphoma, run by Guangzhou Lupeng Pharmaceutical Company LTD., now recruiting.
A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies is a phase 1/2 interventional study registered as NCT07609862 by Guangzhou Lupeng Pharmaceutical Company LTD., with 92 participants planned, started 2026-07-14 and due to reach its primary completion in 2029-06-30. Interventions recorded: Lacutoclax+Rocbrutinib. Conditions listed: Mantle Cell Lymphoma (MCL), Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma ( FL), Waldenström Macroglobulinemia (WM). No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Rocbrutinib, Lupeng Pharmaceuticals, Mantle cell lymphoma.
Shares Rocbrutinib, Lupeng Pharmaceuticals, Mantle cell lymphoma.
Shares Rocbrutinib, Lupeng Pharmaceuticals, Diffuse large B-cell lymphoma.
Shares Lupeng Pharmaceuticals, Mantle cell lymphoma, Follicular lymphoma, Diffuse large B-cell lymphoma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/